SEARLE

Research in the service of mankind

Quarterly Report

September 2026

Elevating life by advancing health
& well-being for generations to come

CONTENTS

Company Information	02
Directors' Review Report Unconsolidated	03
Directors' Review Report (Urdu) Unconsolidated	06
Unconsolidated Statement of Financial Position	07
Unconsolidated Statement of Profit or Loss and Other Comprehensive Income	08
Unconsolidated Statement of Changes in Equity	09

CONTENTS

Unconsolidated Statement of Cash Flows	10
Notes to the Unconsolidated Financial Statements	11
Consolidated Financial Statements	23

Company Information

Board of Directors

Mr. Arshad Anis
Mr. Tahir Ahmed — Chief Executive Officer
Mr. Munis Abdullah
Mr. S. Nadeem Ahmed
Mr. Zubair Razzak Palwala
Ms. Shaista Khaliq Rehman
Ms. Ameena Saiyid

Board of Audit Committee

Ms. Shaista Khaliq Rehman
Mr. Zubair Razzak Palwala
Mr. Munis Abdullah

Board of HR & Remuneration Committee

Ms. Ameena Saiyid
Mr. Munis Abdullah
Ms. Shaista Khaliq Rehman

Chief Financial Officer

Mr. S. Asim Raza Zaidi

Company Secretary

Mr. Mudassir Habib Khan

Auditors

KPMG Taseer Hadi & Co.

Legal Advisors

Mohsin Tayebaly & Co.

Bankers

Faysal Bank Limited
Habib Bank Limited
Al Baraka Bank (Pakistan) Limited
Askari Bank Limited
Bank Alfalah Limited
Dubai Islamic Bank Limited
United Bank Limited
National Bank of Pakistan
The Bank of Punjab
Habib Metropolitan Bank Limited
Bank Islami Pakistan Limited
Pak China Investment Company Limited
Soneri Bank Limited
Bank AL Habib Limited
Meezan Bank Limited

Registered Office

One IBL Centre, 2nd Floor,
Plot # 1, Block 7 & 8
D.M.C.H.S.,
Tipu Sultan Road,
Off Shahra-e-Faisal
Karachi

Share Registrar

CDS Share Registrar
Services Limited
Head Office, CDC House,
99-B, Block 'B'
S.M.C.H.S., Main
Shahrah-e-Faisal
Karachi–74400

Directors' Report to the Members – Unconsolidated

We are pleased to present the unconsolidated interim financial information of the company for the three months ended September 30, 2026. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 – 'Interim Financial Reporting'. The directors' report is prepared in accordance with section 227 of the Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.

Financial highlights

The Company reported revenue of Rs. 8.45 billion, reflecting a marginal decline compared to the corresponding period last year. This is primarily attributable to the transfer of the Company's biological and associated brands, together with the related marketing authorisation rights, to its indirect subsidiary, Searle Biopharma (Private) Limited (formerly Nextar Pharma (Private) Limited) during FY2026. Moreover, the absence of export sales to Afghanistan during the quarter also contributed to revenue decline during the period.

The gross profit margin stood at 55.67%, compared to 55.90% in the corresponding period last year. Despite the transfer of brands to the subsidiary, the Company sustained a strong gross profit margin, reflecting the positive impact of price adjustments and a favourable product sales mix.

Distribution and administrative expenses declined by 3% year-on-year, reflecting the Company's continued focus on cost discipline and operational efficiency. Consequently, profit from operations remained broadly stable at Rs. 1.69 billion, compared to Rs. 1.68 billion in the corresponding period last year.

The Company recorded a profit after tax of Rs. 866 million, compared to Rs. 854 million in the corresponding period last year.

A summary of the financial results for the three months ended September 30, 2026, is presented below:

	Quarter ended	
	September 30, 2026	**September 30, 2025**
	(Rupees in thousand)	
Revenue from contracts with customers	8,452,699	8,567,319
Cost of sales	(3,747,394)	(3,777,796)
Gross Profit	**4,705,305**	**4,789,523**
Distribution costs	(2,353,302)	(2,614,501)
Administrative expenses	(594,795)	(414,016)
Other expenses	(118,740)	(118,882)
Other income	55,424	36,123
Profit from operations	**1,693,892**	**1,678,247**
Finance cost	(296,348)	(279,035)
Profit before levies and income tax	**1,397,544**	**1,399,212**
Levies – minimum tax and final tax	(3,787)	(11,547)
Profit before income tax	**1,393,757**	**1,387,665**
Income tax (expense)/credit	(528,219)	(534,145)
Profit for the period	**865,538**	**853,520**

EARNINGS PER SHARE

Basic earnings per share after taxation for the period is Rs. 1.47 (September 2025: Rs. 1.45). There is no dilution effect on the basic earnings per share of the Company, as the Company had no convertible dilutive potential ordinary shares outstanding as at September 30, 2026.

FUTURE OUTLOOK

Searle enters FY2027 focused on sustaining growth, strengthening operational performance and advancing its strategic priorities. The Company will continue to build on its established pharmaceutical portfolio, introduce differentiated medicines and enhance its presence in international markets, while maintaining a strong focus on profitability and long-term value creation.

Strengthening manufacturing capabilities remains a key priority. The Company will continue to improve operational efficiency, enhance quality standards and optimize capacity utilization, while leveraging toll manufacturing to maximize the productive use of existing facilities. The specialized medicines portfolio, together with Searle Biopharma, provides a platform for advancing the Company's biological medicines business and pursuing opportunities for partnerships and future growth.

Exports will remain an important avenue for expansion, with export sales recording strong growth during the quarter compared to the corresponding period last year. The Company will continue to strengthen its presence in existing markets and pursue product registrations in new geographies, supported by enhanced regulatory capabilities, reliable supply chains and a continued focus on manufacturing standards.

We thank our shareholders for their continued trust and support. Searle remains committed to disciplined execution, innovation, and creating enduring value for all stakeholders.

For and on behalf of the Board

Tahir Ahmed
Chief Executive Officer

Arshad Anis
Director

Karachi: October 21, 2026

فی حصص آمدنی

اس مدت کے لیے ٹیکس کے بعد فی شیئر بنیادی آمدنی 1.47 روپے ہے (30 ستمبر 2025: 1.45 روپے)۔ کمپنی کی فی حصص بنیادی آمدنی پر کسی قسم کی کمی کا اثر نہیں ہوا، کیونکہ 30 ستمبر 2026 تک کمپنی کے پاس کوئی قابل تبدیل ممکنہ عام حصص موجود نہیں تھے۔

مستقبل کا جائزہ

سرل (Searle) مالی سال 2027 میں ترقی کو برقرار رکھنے، عملی کارکردگی کو مضبوط بنانے اور اپنی اسٹریٹجک ترجیحات کو آگے بڑھانے پر توجہ مرکوز کرتے ہوئے داخل ہو رہا ہے۔ کمپنی اپنے قائم شدہ فارماسیوٹیکل پورٹ فولیو کو مزید آگے بڑھانے، منفرد ادویات متعارف کرانے اور بین الاقوامی منڈیوں میں اپنی موجودگی کو بہتر بنانے کا سلسلہ جاری رکھے گی، جبکہ منافع بخش اور طویل مدتی قدر کی تخلیق پر گہری توجہ برقرار رکھے گی۔

مینوفیکچرنگ کی صلاحیتوں کو مضبوط بنانا ایک کلیدی ترجیح بنی ہوئی ہے۔ کمپنی عملی کارکردگی کو بہتر بنانے، معیار کے اصولوں کو بلند کرنے اور صلاحیت کے استعمال کو بہتر بنانے کا سلسلہ جاری رکھے گی، جبکہ موجودہ سہولیات کے پیداواری استعمال کو زیادہ سے زیادہ بڑھانے کے لیے ٹول مینوفیکچرنگ (Toll Manufacturing) سے فائدہ اٹھائے گی۔ خصوصی ادویات کا پورٹ فولیو، سرل بائیو فارما کے ساتھ مل کر، کمپنی کے بائیولوجیکل ادویات کے کاروبار کو آگے بڑھانے اور شراکت داری اور مستقبل کی ترقی کے مواقع تلاش کرنے کے لیے ایک پلیٹ فارم فراہم کرتا ہے۔

برآمدات توسیع کا ایک اہم ذریعہ بنی رہیں گی، اور اس سہ ماہی کے دوران گزشتہ سال کے اسی عرصے کے مقابلے میں برآمدی فروخت میں شاندار اضافہ ریکارڈ کیا گیا۔ کمپنی بہتر ریگولیٹری صلاحیتوں، قابل بھروسہ سپلائی چینز اور مینوفیکچرنگ کے معیارات پر مسلسل توجہ کی حمایت سے، موجودہ منڈیوں میں اپنی موجودگی کو مضبوط بنانا اور نئے خطوں میں مصنوعات کی رجسٹریشن کا عمل جاری رکھے گی۔

ہم اپنے شیئر ہولڈرز کا ان کے مسلسل اعتماد اور تعاون پر شکریہ ادا کرتے ہیں۔ سرل باقاعدہ نفاذ، جدت اور تمام اسٹیک ہولڈرز کے لیے پائیدار قدر پیدا کرنے کے لیے پرعزم ہے

بورڈ کے لیے اور اس کی جانب سے

طاہر احمد
چیف ایگزیکٹو آفیسر

ارشد انیس
ڈائریکٹر

کراچی: 21 اکتوبر 2026

غیر متفقہ ڈائریکٹرز رپورٹ برائے حصص یافتگان

ہمیں خوشی ہے کہ ہم کمپنی کی 30 ستمبر 2026 کو ختم ہونے والی سہ ماہی کے غیر متفقہ شدہ عبوری مالیاتی گوشوارے پیش کر رہے ہیں۔ یہ مالیاتی گوشوارے بین الاقوامی اکاؤنٹنگ اسٹینڈرڈ "34 (IAS) – عبوری مالیاتی رپورٹنگ" کے تقاضوں کے مطابق تیار کیے گئے ہیں۔ ڈائریکٹرز کی یہ رپورٹ کمپنیز ایکٹ 2017 کی دفعہ 227 اور لسٹڈ کمپنیز (کارپوریٹ گورننس کے ضابطہ اخلاق) ریگولیشنز 2019 کے باب XII کے تحت تیار کی گئی ہے۔

مالی جھلکیاں

کمپنی نے 8.45 ارب روپے کی آمدنی رپورٹ کی، جو گزشتہ سال کے اسی عرصے کے مقابلے میں معمولی کمی ظاہر کرتی ہے۔ یہ کمی بنیادی طور پر مالی سال 2026 کے دوران کمپنی کے بائیولوجیکل اور متعلقہ برانڈز، بشمول مارکیٹنگ کے مجاز حقوق، کی اس کی بالواسطہ ذیلی کمپنی 'سرل بائیو فارما (پرائیویٹ) لمیٹڈ' (سابقہ نیکسٹار فارما (پرائیویٹ) لمیٹڈ) کو منتقلی کے باعث ہوئی۔ مزید برآں، اس سہ ماہی کے دوران افغانستان کو برآمدات نہ ہونا بھی اس عرصے کے دوران آمدنی میں کمی کا سبب بنا۔

مجموعی منافع کا مارجن 55.67% رہا، جو گزشتہ سال کے اسی عرصے میں 55.90% تھا۔ ذیلی کمپنی کو برانڈز کی منتقلی کے باوجود، کمپنی نے مجموعی منافع کے مضبوط مارجن کو برقرار رکھا، جو قیمتوں میں ایڈجسٹمنٹ اور مصنوعات کی فروخت کے مجموعے میں سازگار تبدیلی کے مثبت اثرات کو ظاہر کرتا ہے۔

تقسیمی اور انتظامی اخراجات میں سال بہ سال 3% کمی واقع ہوئی، جو لاگت میں ڈسپلن اور عملی کارکردگی پر کمپنی کی مسلسل توجہ کی عکاسی کرتی ہے۔ نتیجتاً، آپریٹنگ منافع 1.69 ارب روپے پر بڑے پیمانے پر مستحکم رہا، جو گزشتہ سال کے اسی عرصے میں 1.68 ارب روپے تھا۔

کمپنی نے بعد از ٹیکس 866 ملین روپے کا منافع ریکارڈ کیا، جو گزشتہ سال کے اسی عرصے میں 854 ملین روپے تھا۔

ذیل میں 30 ستمبر 2026 کو ختم ہونے والے تین ماہ کے مالیاتی نتائج کا خلاصہ پیش کیا جا رہا ہے:

	اختتام پذیر سہ ماہی	
	30 ستمبر 2026	30 ستمبر 2025
	(پاکستانی روپے ہزاروں میں)	
گاہکوں کے ساتھ معاہدوں سے آمدنی	8,452,699	8,567,319
فروخت کی لاگت	(3,747,394)	(3,777,796)
مجموعی منافع	**4,705,305**	**4,789,523**
ترسیل کے اخراجات	(2,353,302)	(2,614,501)
انتظامی اخراجات	(594,795)	(414,016)
دیگر اخراجات	(118,740)	(118,882)
دیگر آمدنی	55,424	36,123
آپریٹنگ منافع	**1,693,892**	**1,678,247**
مالیاتی اخراجات	(296,348)	(279,035)
لیویز اور انکم ٹیکس سے قبل منافع	**1,397,544**	**1,399,212**
لیویز – کم از کم ٹیکس اور حتمی ٹیکس	(3,787)	(11,547)
انکم ٹیکس سے قبل منافع	**1,393,757**	**1,387,665**
انکم ٹیکس (اخراجات) / کریڈٹ	**(528,219)**	**(534,145)**
اس عرصے کا منافع	**865,538**	**853,520**

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION

As at September 30, 2026

ASSETS	Note	(Un-audited) September 30 2026	(Audited) June 30 2026
		(Rupees in '000)	
Non-current assets			
Property, plant and equipment	5	**8,245,723**	8,299,183
Right-of-use assets		**28,555**	31,110
Investment properties - at cost		**2,829,309**	2,844,578
Intangible assets		**308**	326
Deferred tax assets		**173,877**	174,816
Long-term investments - subsidiaries	6	**12,348,318**	12,348,318
Long-term loans and deposits		**7,396**	7,404
		23,633,486	23,705,735
Current assets			
Inventories		**4,806,269**	5,233,605
Trade receivables	7	**10,999,147**	9,594,900
Loans and advances	8	**5,131,367**	3,763,780
Trade deposits and short-term prepayments		**338,754**	302,327
Other receivables	9	**2,722,765**	3,142,522
Short-term investment - at amortised cost		**-**	400,000
Taxation - payments less provision		**1,512,806**	1,841,792
Tax refunds due from Government - sales tax		**189,078**	224,193
Cash and bank balances		**1,163,171**	1,574,996
		26,863,357	26,078,115
Total assets		**50,496,843**	49,783,850
EQUITY AND LIABILITIES			
EQUITY			
Share Capital			
Issued, subscribed and paid-up capital		**5,882,186**	5,882,186
Capital Reserves			
Share premium		**9,085,133**	9,085,133
Revaluation surplus on property, plant and equipment - net		**4,792,813**	4,873,315
Revenue reserves			
General reserve		**280,251**	280,251
Unappropriated profit		**15,625,747**	14,679,707
Total equity		**35,666,130**	34,800,592
LIABILITIES			
Non-current liabilities			
Employee benefit obligations		**52,904**	58,506
Long-term borrowings	10	**116,457**	125,892
Lease liability		**40,337**	43,470
		209,698	227,868
Current liabilities			
Trade and other payables	11	**5,301,452**	6,456,216
Short-term borrowings	12	**9,013,094**	8,034,445
Contract liabilities		**74,344**	32,186
Unpaid dividend		**181,717**	181,909
Unclaimed dividend		**36,364**	36,590
Current portion of lease liability		**14,044**	14,044
		14,621,015	14,755,390
Total liabilities		**14,830,713**	14,983,258
Contingencies and commitments	13		
Total equity and liabilities		**50,496,843**	49,783,850

The annexed notes from 1 to 21 form an integral part of these condensed interim financial statements.

Chief Executive | Director | Chief Financial Officer

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the period ended September 30, 2026 - Unaudited

	Note	September 30 2026	September 30 2025
		(Rupees in '000)	
Revenue from contracts with customers	14	**8,452,699**	8,567,319
Cost of sales		**(3,747,394)**	(3,777,796)
Gross profit		**4,705,305**	4,789,523
Distribution costs		**(2,353,302)**	(2,614,501)
Administrative expenses		**(594,795)**	(414,016)
Other expenses		**(118,740)**	(118,882)
Other income		**55,424**	36,123
Profit from operations		**1,693,892**	1,678,247
Finance cost		**(296,348)**	(279,035)
Profit before levies and income tax		**1,397,544**	1,399,212
Levies - minimum tax and final tax		**(3,787)**	(11,547)
Profit before income tax		**1,393,757**	1,387,665
Income tax (expense)/credit		**(528,219)**	(534,145)
Profit for the period		**865,538**	853,520
Total comprehensive income		**865,538**	853,520
			(Re-stated)
Earnings per share - basic and diluted	15	**1.47**	1.45

The annexed notes from 1 to 21 form an integral part of these condensed interim financial statements.

Chief Executive | Director | Chief Financial Officer

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY

For the period ended September 30, 2026 - Unaudited

		Capital reserve		Revenue reserves			
	Issued, subscribed and paid-up capital	Share premium	Revaluation surplus on Property, plant & equipment	General reserve	Unappropriated profits	Total reserves	Total
	Rupees '000						
Balance as at July 01, 2025	5,114,945	9,085,133	4,582,517	280,251	11,176,837	25,124,738	30,239,683
Transfer of incremental depreciation for the period (net of deferred tax)	-	-	(60,797)	-	60,797	-	-
Total comprehensive income for the period	-	-	-	-	853,520	853,520	853,520
Balance as at September 30, 2025	5,114,945	9,085,133	4,521,720	280,251	12,091,154	25,978,258	31,093,203
Balance as at July 01, 2026	**5,882,186**	**9,085,133**	**4,873,315**	**280,251**	**14,679,707**	**28,918,406**	**34,800,592**
Transfer of incremental depreciation for the period (net of deferred tax)	-	-	**(80,502)**	-	**80,502**	**-**	**-**
Total comprehensive income for the period	**-**	**-**	**-**	**-**	**865,538**	**865,538**	**865,538**
Balance as at September 30, 2026	**5,882,186**	**9,085,133**	**4,792,813**	**280,251**	**15,625,747**	**29,783,944**	**35,666,130**

The annexed notes from 1 to 21 form an integral part of these condensed interim financial statements.

Chief Executive

Director

Chief Financial Officer

UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF CASH FLOWS

For the period ended September 30, 2026 - Unaudited

	Note	September 30 2026	September 30 2025
		(Rupees in '000)	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	16	**(1,785,079)**	756,406
Employees benefit obligations paid		**(6,952)**	(1,942)
Finance cost paid		**(271,323)**	(255,666)
Income taxes paid		**(202,081)**	(96,076)
Long-term loans & deposits		**8**	15
Net cash generated from operating activities		**(2,265,427)**	402,737
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		**(144,758)**	(91,203)
Proceeds from disposal of property, plant and equipment		**-**	45
Addition to investment properties		**(9,783)**	(454)
Proceeds from disposal of subsidiary		**650,000**	150,000
Proceeds / (purchase) of short-term investments		**-**	100,000
Net cash used in investing activities		**495,459**	158,388
CASH FLOWS FROM FINANCING ACTIVITIES			
Dividend paid		**(418)**	(124)
Proceeds/(repayment) of short term finance facility		**-**	(300,000)
Proceeds/(repayment) of long-term borrowings		**(8,393)**	(3,276)
Proceeds of short-term islamic finance (Sukuk)		**2,250,000**	-
(Repayment) of running musharaka and export refinance		**(322,411)**	(105,609)
Payment against lease liabilities		**(10,653)**	(7,407)
Net cash from financing activities		**1,908,125**	(416,416)
Net increase in cash and cash equivalents		**138,157**	144,709
Cash and cash equivalents at the beginning of the period		**678,073**	(1,154,995)
Cash and cash equivalents at the end of the period	17	**816,230**	(1,010,286)

The annexed notes from 1 to 21 form an integral part of these condensed interim financial statements.

Chief Executive | Director | Chief Financial Officer

1. THE COMPANY AND ITS OPERATIONS

1.1 The Searle Company Limited (the Company) was incorporated in Pakistan as a private limited company in October 1965. In November 1993, the Company was converted into a public limited company under the repealed Companies Ordinance, 1984 (now the Companies Act, 2017). Its shares are quoted on the Pakistan Stock Exchange Limited (PSX). The Company is principally engaged in the manufacturing of pharmaceutical and other consumer products. The registered office of the Company is situated at One IBL Centre 2nd Floor, Plot No. 1, Block 7 & 8 Dehli Mercantile Muslim Cooperative Housing Society, Tipu Sultan Road off Shahrah-e-Faisal, Karachi.

International Brands (Private) Limited is the Parent Company, which holds 50.23% (June 30, 2026: 50.03%) shareholding in the Company.

1.2 Following are the subsidiary companies:

	Principal place of business	Effective %age of holding	
		September 30 2026	June 30 2026
Listed Company			
- IBL HealthCare Limited	Pakistan	**74.19%**	74.19%
Unlisted Companies			
- Searle Pharmaceuticals (Private) Limited		**100.00%**	100.00%
- Searle Laboratories (Private) Limited		**100.00%**	100.00%
- Searle Biosciences (Private) Limited		**100.00%**	100.00%
- IBL Future Technologies (Private) Limited		**100.00%**	100.00%
- Searle IV Solutions (Private) Limited		**100.00%**	100.00%
- Stellar Ventures (Private) Limited		**100.00%**	100.00%
- Mycart (Private) Limited *		**50.00%**	50.00%
- IBL Frontier Markets (Private) Limited *		**100.00%**	100.00%
- Prime Health (Private) Limited *		**100.00%**	100.00%
- Searle Biopharma (Private) Limited [formerly Nextar Pharma (Private) Limited] **		**87.20%**	87.20%

***** *Searle Biopharma (Private) Limited is the subsidiary of Searle Biosciences (Private) Limited being the indirect subsidiary of the Company.*

***** *Mycart (Private) Limited, IBL Frontier Markets (Private) Limited and Prime Health (Private) Limited are the subsidiaries of Stellar Ventures (Private) Limited being the indirect subsidiaries of the Company.*

1.3 These unconsolidated condensed interim financial statements are separate financial statements of the Company in which investments in subsidiaries have been accounted for at cost less accumulated impairment losses, if any.

2. BASIS OF PREPARATION

2.1 Statement of compliance

2.1.1 These unconsolidated condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and

- Provisions of and directives issued under the Companies Act, 2017

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

2.1.2 These unconsolidated condensed interim financial statements do not include all the information required for a full set of financial statements and should be read in conjunction with the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2026.

2.1.3 Functional and presentation currency

These unconsolidated condensed interim financial statements are presented in Pakistan Rupees which is the Company's functional and presentation currency. All financial information presented in Pakistani Rupees have been rounded off to the nearest thousand Rupees except where stated otherwise.

3. MATERIAL ACCOUNTING POLICY INFORMATION

3.1 The accounting policies and methods of computation adopted in the preparation of these unconsolidated condensed interim financial statements are the same as those applied in the preparation of the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2026.

3.2 Changes in accounting standards, interpretations and pronouncements

a) Standards and amendments to approved accounting standards that are effective

There are certain standards, amendments and interpretations to the accounting and reporting standards which are mandatory for the Company's annual accounting period which began on July 1, 2026. However, these do not have any significant impact on the Company's financial reporting.

b) Standards and amendments to approved accounting standards that are not yet effective

There are certain new standards and amendments that will be applicable to the Company for its annual periods beginning on or after July 1, 2027. However, these will not have any impact on the Company's financial reporting and, therefore, have not been disclosed in these unconsolidated condensed interim financial statements.

4. ACCOUNTING ESTIMATES AND JUDGEMENTS AND FINANCIAL RISK MANAGEMENT

4.1 The preparation of the unconsolidated condensed interim financial statements in conformity with accounting and reporting standards, as applicable in Pakistan, requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

4.2 The significant judgements made by the management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the audited annual unconsolidated financial statements as at and for the year ended June 30, 2026.

4.3 The Company's financial risk management objectives and policies are consistent with those disclosed in the audited annual unconsolidated financial statements for the year ended June 30, 2026.

5. PROPERTY, PLANT AND EQUIPMENT

	(Unaudited) September 30 2026	(Audited) June 30 2026
	(Rupees in '000)	
Operating assets - note 5.1	**7,610,035**	7,749,508
Capital work-in-progress - at cost	**635,688**	549,675
	8,245,723	8,299,183

5.1 Details of additions in operating assets including transfers from capital work-in-progress during the period are as follows:

	Additions (at cost)		**Disposals (at net book value)**	
	Sep. 30, 2026	Sep. 30, 2025	**Sep. 30, 2026**	Sep. 30, 2025
	(Rupees in '000)			
Building on leasehold land	**848**	2,658	**-**	-
Plant and machinery	**1,856**	230	**-**	-
Furniture & fittings	**3,630**	552	**-**	-
Office equipment	**52,412**	15,654	**-**	(262)
	58,746	19,094	**-**	(262)

6. LONG-TERM INVESTMENTS - SUBSIDIARIES

	(Unaudited) September 30 2026	(Audited) June 30 2026
	(Rupees in '000)	
Subsidiary companies (at cost)	**12,348,318**	12,348,318

6.1 Subsidiary companies

	September 30, 2026		June 30, 2026	
	Equity % held	Investment at cost (Rupees '000)	Equity % held	Investment at cost (Rupees '000)
Quoted security				
IBL HealthCare Limited				
73,093,957 (June 30, 2026: 73,093,957) Ordinary shares of Rs. 10 each	74.19%	1,300,911	74.19%	1,300,911
Market price as at September 30, 2026: Rs. 42.64 (June 30, 2026: Rs. 98.51) per share				
Unquoted securities				
Searle Biosciences (Private) Limited				
30,000,000 (June 30, 2026: 11,000,000) Ordinary shares of Rs. 10 each	100%	4,590,000	100%	790,000
Advance against issue of shares		-		3,800,000
Break up value as at September 30, 2026: Rs. 156.49 (June 30, 2026: Rs. 426.84) per share		4,590,000		4,590,000
IBL Future Technologies (Private) Limited				
20,000,000 (June 30, 2026: 20,000,000) Ordinary shares of Rs. 10 each	100%	200,000	100%	200,000
Break up value as at September 30, 2026: Rs. 10.03 (June 30, 2026: Rs. 10.03) per share				
Searle Laboratories (Private) Limited				
12,500,000 (June 30, 2026: 12,500,000) Ordinary shares of Rs. 10 each	100%	125,000	100%	125,000
Provision for impairment loss		(125,000)		(125,000)
Break up value as at September 30, 2026: Rs. 0.22 (June 30, 2026: Rs. 0.22) per share		-		-
Searle Pharmaceuticals (Private) Limited				
40,000 (June 30, 2026: 40,000) Ordinary shares of Rs. 10 each	100%	400	100%	400
Provision for impairment loss		(400)		(400)
Break up value as at September 30, 2026: nil (June 30, 2026: nil) per share		-		-
Stellar Ventures (Private) Limited				
12,100,000 (June 30, 2026: 12,100,000) Ordinary shares of Rs. 10 each	100%	3,750,407	100%	3,750,407
Provision for impairment loss		(993,000)		(993,000)
Break up value as at September 30, 2026: Rs. 331.41 (June 30, 2026: 331.41) per share		2,757,407		2,757,407
Searle IV Solutions (Private) Limited				
5,400,000 (June 30, 2026: 5,400,000) Ordinary shares of Rs. 100 each	100%	3,500,000	100%	3,500,000
Break up value as at September 30, 2026: Rs. 305.28 (June 30, 2026: 301.56) per share				
		11,047,407		11,047,407
		12,348,318		12,348,318

7 TRADE RECEIVABLES

Considered good		
- Due from related parties, unsecured - note 7.1	8,124,795	7,570,261
- Export receivables - secured	903,074	608,210
- others - unsecured	2,174,779	1,619,930
	11,202,648	9,798,401
Less: allowance for expected credit losses	(203,501)	(203,501)
	10,999,147	9,594,900

8 LOANS AND ADVANCES

8.1 These include advances to Searle Biosciences (Private) Limited amounting to Rs. 2,001.19 million (June 30, 2026: Rs. 1,004.39 million), Searle IV Solutions (Private) Limited amounting to Rs. 1,498.24 million (June 30, 2026: Rs. 1,300.75 million), Stellar Ventures (Private) Limited amounting to Rs. 313.24 million (June 30, 2026: Rs. 280.24 million), and Searle Pharmaceuticals (Private) limited amounting to Rs. 144.17 million (June 30, 2026 : Rs. 144.17 million, wholly owned subsidiaries. These are provided for and settled in the normal course of business.

9 OTHER RECEIVABLES

	(Unaudited) September 30 2026	(Audited) June 30 2026
	(Rupees in '000)	
Receivables from related parties		
Due from subsidiary companies:		
IBL Healthcare Limited against:		
Royalty	**37,779**	35,279
Rental income	**2,965**	-
Searle Biosciences (Private) Limited against:		
Facility Management Fee	**151,585**	220,000
Expenses	**-**	171,052
Searle IV Solutions (Private) Limited against Expenses	**7,279**	73,081
Searle Biopharma (Private) Limited against:		
Expenses	**31,542**	99,963
Facility Management Fee	**550,000**	-
Sale of Brands	**-**	200,000
	781,150	799,375
Due from parent company		
International Brands (Private) Limited against:		
Expenses	**376,397**	306,091
Rental income	**5,906**	-
	382,303	306,091
Due from associated companies		
IBL Operations (Private) Limited against:		
Expenses	**2,942**	1,848
Rental income	**3,690**	666
IBL Unisys (Private) Limited against:		
Rental income	**109**	-
United Brands Limited against:		
Expenses	**50**	50
IBL Logistics (Private) Limited against:		
Expenses	**252**	252
Universal Ventures (Private) Limited against:		
Sale of subsidiary	**86,452**	86,452
Due from other related party:		
United Retail (SMC-Private) Limited against:		
Rental income	**15,614**	14,216
Expenses	**136,517**	116,390
Universal Retail (Private) Limited against:		
Rental income	**64,903**	55,836
Expenses	**204,666**	187,749
	515,195	463,459
Surplus arising under retirement benefit fund	**5,250**	5,250
Receivables from other than related parties		
Noventa Pharma (Private) Limited against:		
Sale of subsidiary	**751,121**	1,401,121
Others, considered good	**287,746**	167,226
	2,722,765	3,142,522

		(Unaudited) September 30 2026	(Audited) June 30 2026
10.	**LONG-TERM BORROWINGS**	(Rupees in '000)	
	Diminishing Musharika	**116,457**	125,892

10.1. During the last year, the Company obtained diminishing musharakah financing of Rs. 145 million from First Habib Modaraba for acquisition of four vehicles. The facilities carry profit at 3 month KIBOR plus 1% (with a minimum of 5%) and are repayable over a five years term through a monthly buy out of Musharakah units.

10.2. These arrangements are secured through hypothecation over the financed vehicles, comprehensive takaful assigned to the Modaraba, and retention of vehicle title in the name of First Habib Modaraba until full settlement.

		(Unaudited) September 30 2026	(Audited) June 30 2026
11.	**TRADE AND OTHER PAYABLES**	(Rupees in '000)	
	Creditors	**1,229,090**	1,502,355
	Bills payable in foreign currency	**662,117**	1,042,346
	Payable to related parties	**3,745**	23,471
	Royalty payable	**29,476**	39,868
	Accrued liabilities	**1,914,667**	2,292,907
	Payable to provident fund	**25,520**	26,890
	Accrued mark-up	**244,231**	226,727
	Taxes deducted at source and payable to statutory authorities	**652,294**	844,641
	Workers' Profit Participation Fund	**302,470**	226,656
	Workers' Welfare Fund	**129,450**	100,641
	Other liabilities	**108,392**	129,714
		5,301,452	6,456,216

12. SHORT-TERM BORROWINGS	(Unaudited) September 30 2026	(Audited) June 30 2026
	(Rupees in '000)	
Secured borrowings		
Conventional		
Running finance facility - note -12.1	**346,941**	1,296,923
Export re-finance	**-**	100,000
Short-term finance facility	**500,000**	500,000
	846,941	1,896,923
Islamic		
Running Musharaka	**4,528,723**	5,801,134
Current portion of long-term borrowings - note -12.1.1	**37,430**	36,388
Export re-finance	**1,150,000**	100,000
	5,716,153	5,937,522
	6,563,094	7,834,445
Unsecured		
Borrowing from IBL Future Technologies (Private) Limited - note 12.2	**200,000**	200,000
Short-term Islamic finance (Sukuk) - note 12.3	**2,250,000**	-
	9,013,094	8,034,445

12.1 The Company has entered into running finance under mark-up arrangements from various banks amounting to Rs. 10,200 million (June 30, 2026: Rs. 9,700 million) which include financing facilities obtained under Islamic mode amounting to Rs. 8,650 million (June 30, 2026: Rs. 7,650 million). The arrangements are secured jointly by a registered mortgage of Rs. 2,642 million (June 30, 2026: Rs. 2,813.5 million) of immovable property together with a joint pari passu charge on all current assets of the Company to the extent of Rs. 14,890 million (June 30, 2026: Rs. 14,583.67 million).

12.1.1 The rates of mark-up ranged between 12.90 % to 13.79 % (June 30, 2026: 11.74% to 13.99%) per annum.

12.1.2 The rates of profit ranged between 12.19 % to 13.29 % (June 30, 2026: 10.58% to 13.03%) per annum.

12.2 This represents interest free loan obtained from IBL Future Technologies (Private) Limited - wholly owned subsidiary and is repayable on demand.

12.3 During the period, the Company has obtained short-term financing in the form of Sukuk amounting to Rs. 2,250 million under a Shariah-compliant Islamic financing arrangement for meeting its working capital and general business requirements. The financing is unsecured, privately placed and taken as a redeemable capital under Section 66 of the Companies Act 2017. The tenor of this financing is 6 months and is priced at 3 months Kibor + 0.75% which is payable at maturity along with the principal.

13. CONTINGENCIES AND COMMITMENTS

13.1 Contingencies

There has been no significant change in the status of contingencies in the current period as reported in the note 28 of the annual audited unconsolidated financial statements of the Company for the year ended June 30, 2026.

13.2 Commitments

	(Unaudited) September 30 2026	(Audited) June 30 2026
	(Rupees in '000)	
13.2.1 Commitments in respect of capital expenditures		
Property, plant and equipment	**26,168**	26,552

13.2.2 Post-dated cheques issued in favour of Collector of Customs for import of inventory as at September 30, 2026 amounted to Rs. 354.68 million (June 30, 2026: Rs. 538.95 million).

13.2.3 The facility for opening letters of credit and guarantees as at September 30, 2026 amounted to Rs. 4,295 million (June 30, 2026: Rs. 4,015 million) of which the amount remaining unutilised as at period ended September 30, 2026 amounted to Rs. 2,955 million (June 30, 2026: Rs. 2,716 million).

14. REVENUE FROM CONTRACTS WITH CUSTOMERS

	September 30 2026	September 30 2025
	(Rupees in '000)	
Gross sales		
Local sale of goods	**8,488,190**	8,588,311
Export sales	**1,081,954**	851,775
	9,570,144	9,440,086
Toll manufacturing	**7,931**	1,245
	9,578,075	9,441,331
Sales tax	**(89,860)**	(113,461)
	9,488,215	9,327,870
Less:		
Trade discount	**(701,347)**	(440,074)
Sales return	**(334,169)**	(320,477)
	(1,035,516)	(760,551)
	8,452,699	8,567,319

15. BASIC AND DILUTED EARNINGS PER SHARE

Profit for the period (Rupees in thousands)	**865,538**	853,520
Weighted average number of outstanding shares at the end of period (in thousand) - Restated	**588,219**	588,219
		(Re-stated)
Basic and diluted earnings/(loss) per share (Rupees)	**1.47**	1.45

		September 30 2026	September 30 2025
16.	**CASH GENERATED FROM OPERATIONS**	(Rupees in '000)	
	Profit before levies and income tax	**1,397,544**	1,399,212
	Add adjustments for non-cash charges and other items		
	Depreciation	**225,825**	173,468
	Loss on disposal of property, plant and equipment	**-**	217
	Amortisation of intangible assets	**18**	3,054
	Provision for retirement benefits obligation	**1,350**	1,350
	Finance cost	**288,827**	264,956
	Interest on lease liability	**7,520**	4,684
	Profit before working capital changes	**1,921,084**	1,846,941
	Effect on cash flow due to working capital changes		
	(Increase) / decrease in current assets		
	Inventories	**427,336**	(157,215)
	Trade receivables	**(1,404,247)**	(931,741)
	Loans and advances	**(1,367,587)**	(209,080)
	Trade deposits and short-term prepayments	**(36,427)**	(67,974)
	Other receivables	**(230,243)**	21,787
	Refund due from Government - sales tax - net	**35,115**	70,236
		(2,576,053)	(1,273,987)
	Increase / (decrease) in current liabilities		
	Trade and other payables	**(1,172,268)**	180,747
	Contract liabilities	**42,158**	2,705
		(1,130,110)	183,452
	Cash flows generated from operations	**(1,785,079)**	756,406
17.	**CASH AND CASH EQUIVALENTS**		
	Cash and bank balances	**1,163,171**	151,273
	Running finance under markup arrangements - note 12.1	**(346,941)**	(1,161,559)
		816,230	(1,010,286)

17.1 Short-term borrowings other than running finance have been reclassified as financing activities in the statement of cash flows which were previously included as cash and cash equivalents.

18. SEGMENT INFORMATION

Based on internal management reporting structure for the period, no reportable segments were identified that were of continuing significance for decision making.

19. DISCLOSURE OF TRANSACTIONS BETWEEN THE COMPANY AND RELATED PARTIES:

The related parties include associated companies, staff retirement funds, directors, key management personnel and close family members of directors and key management personnel. The Company in the normal course of business carries out transactions with various related parties.

The Company enters into transactions with related parties on the basis of mutually agreed terms. Significant transactions with related parties are as follows:

Nature of relationship		Nature of transactions	September 30 2026	September 30 2025
			(Rupees in '000)	
Parent company	-	Corporate service charges	**81,150**	24,200
	-	Rent income	**5,906**	5,459
	-	Income from provision of amenities	**4,103**	3,810
Subsidiaries				
	-	Revenue	**375,981**	108,074
	-	Purchase of consumables	**177,251**	313,482
	-	Royalty	**14,000**	-
	-	Advances to Subsidary	**1,385,165**	249,150
	-	Reimbursement of expenses	**34,263**	19,504
	-	Rent income	**1,364**	1,240
	-	Income from Provision of Amenities	**1,601**	804
	-	Management Fees	**15,000**	-
	-	Others	**627**	-
Associated companies				
	-	Revenue	**6,562,784**	6,502,514
	-	Salaries and wages	**2,678**	3,554
	-	Purchases	**606**	3,021
	-	Carriage and duties	**-**	11,091
	-	Discounts claims	**31,200**	935
	-	Rent expense	**21,865**	21,230
	-	Rent income	**15,589**	13,880
	-	Income from Provision of Amenities	**50,650**	38,100
	-	Stock claims	**37,774**	10
	-	Advance against claims	**-**	21,000
	-	Internet services	**27,282**	11,933
	-	Donations	**5,850**	5,000
	-	Incentives to field force staff	**5,704**	-
	-	Repair & maintenance	**284**	153
	-	Purchases of Furniture	**8,018**	-
	-	Others	**2,301**	-

Nature of relationship	Nature of transactions	September 30 2026	September 30 2025
		(Rupees in '000)	
Staff retirement benefits			
	- Contributions to Provident Fund	**69,212**	67,923
	- Benefits paid	**-**	14,283
Key management employees compensation	- Salaries and other employee benefits	**87,489**	70,510
	- Contributions to Provident Fund	**9,672**	9,210

19.1 The status of outstanding balances with related parties as at reporting date is included in the respective notes to the unconsolidated condensed interim financial statements.

20. GENERAL

20.1. Non-adjusting events after reporting date

The Board of Directors, in their meeting held on September 25, 2026, proposed a final cash dividend of Re. 1 per share (Rs. 588.22 million) for the year ended June 30, 2026. The proposal is subject to approval by the members at the Annual General Meeting scheduled to be held on October 22, 2026. In accordance with IAS 10 'Events after the Reporting Period', this proposed dividend has not been recognised as a liability in these condensed interim financial statements.

21. DATE OF AUTHORISATION FOR ISSUE

These unconsolidated condensed interim financial statements were approved and authorised for issue by the Board of Directors of the Company on October 21, 2026.

Chief Executive | Director | Chief Financial Officer

Consolidated Financial Statements

CONTENTS

Consolidated Directors' Report	24
Consolidated Directors' Report (Urdu)	27
Consolidated Statement of Financial Position	28
Consolidated Statement of Profit or Loss and Other Comprehensive Income	29
Consolidated Statement of Changes in Equity	30
Consolidated Statement of Cash Flows	31
Notes to the Consolidated Financial Statements	32

Directors' Report to the Members

We are pleased to present the consolidated interim financial information of the group for the three months ended September 30, 2026. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 – 'Interim Financial Reporting'. The directors' report is prepared in accordance with section 227 of the Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.

Financial highlights

The Group reported revenue of Rs. 11.18 billion, reflecting a growth of 15.24% over last year. The significant growth in sales was underpinned by enhanced operational efficiencies, particularly through optimization of supply chain processes and effective allocation of financial resources. The gross profit margin improved to 57.23%, marking a 3.15 percentage increase year-on-year. This improvement was primarily driven by price adjustments and a favorable shift in the product mix.

Profit from operations increased by 22% year-on-year, driven by higher sales and improved gross profit margins, partially offset by a modest increase in operating expenses.

The Group recorded a profit after tax of Rs. 1,195 million, reflecting a growth of 31% compared to Rs. 914 million in the corresponding period last year.

A summary of the financial results for the three months ended September 30, 2026, is presented below:

	Quarter ended	
	September 30, 2026	**September 30, 2025**
	(Rupees in thousand)	
Revenue from contracts with customers	11,175,336	9,697,271
Cost of sales	(4,779,268)	(4,452,970)
Gross Profit	**6,396,068**	**5,244,301**
Distribution costs	(3,307,409)	(2,843,382)
Administrative expenses	(698,529)	(492,208)
Other expenses	(209,785)	(124,942)
Other income	49,758	39,396
Profit from operations	**2,230,103**	**1,823,165**
Finance cost	(297,453)	(288,407)
Profit before levies and income tax	**1,932,650**	**1,534,758**
Levies – minimum tax and final tax	(4,885)	(20,045)
Profit before income tax	**1,927,765**	**1,514,713**
Income tax (expense)/credit	(732,290)	(600,561)
Profit for the period	**1,195,475**	**914,152**

EARNINGS PER SHARE

Basic earnings per share after taxation for the period is Rs. 1.95 (September 2025: Rs. 1.54). There is no dilution effect on the basic earnings per share of the Group, as the Group had no convertible dilutive potential ordinary shares outstanding as at September 30, 2026.

FUTURE OUTLOOK

The Searle Group enters FY2027 with a focus on translating its growth momentum into sustainable financial performance while strengthening its position across the pharmaceutical value chain. Pakistan's economic recovery, alongside evolving inflationary trends, interest rates and exchange rate dynamics, will continue to shape the operating environment. In this context, the Group will remain focused on navigating cost pressures, improving resource utilisation and maintaining financial discipline.

At the Group level, the focus will be on enhancing operational synergies, improving business performance and optimising the utilisation of available resources across its operations. Continued investment in manufacturing capabilities, quality systems and specialised medicines will support the Group's long-term growth ambitions, while Searle Biopharma provides a dedicated platform for developing the biological medicines business and pursuing strategic partnerships.

International markets will remain an important contributor to the Group's diversification strategy. Building on the strong growth in export sales during the quarter, the Group will seek to strengthen its presence in existing markets and expand into new geographies through product registrations, stronger regulatory capabilities and reliable supply chains.

The Group will continue to pursue a balanced approach to growth, combining business expansion with disciplined cost management, prudent capital allocation and effective working capital management. Through these priorities, the Group aims to strengthen its resilience, enhance shareholder returns and create sustainable long-term value for all stakeholders.

For and on behalf of the Board

Tahir Ahmed
Chief Executive Officer

Arshad Anis
Director

Karachi: October 21, 2026

فی حصص آمدنی

اس مدت کے لیے ٹیکس کے بعد فی شیئر بنیادی آمدنی 1.95 روپے ہے (30 ستمبر 2025: 1.54 روپے)۔ گروپ کی فی حصص بنیادی آمدنی پر کسی قسم کی کمی کا اثر نہیں ہوا، کیونکہ 30 ستمبر 2026 تک گروپ کے پاس کوئی قابلِ تبدیل ممکنہ عام حصص موجود نہیں تھے۔

مستقبل کا جائزہ

سرل (Searle) گروپ اپنے ترقی کے تسلسل کو پائیدار مالیاتی کارکردگی میں تبدیل کرنے اور فارماسیوٹیکل ویلیو چین کے تمام شعبوں میں اپنی پوزیشن مضبوط بنانے پر توجہ مرکوز کرتے ہوئے مالی سال 2027 میں داخل ہو رہا ہے۔ پاکستان کی معاشی بحالی، افراطِ زر کے بدلتے ہوئے رجحانات، شرحِ سود اور شرحِ مبادلہ کے حالات کاروباری ماحول کو متحرک رکھنا جاری رکھیں گے۔ اس تناظر میں، گروپ لاگت کے دباؤ سے نمٹنے، وسائل کے بہتر استعمال اور مالیاتی ڈسپلن کو برقرار رکھنے پر توجہ مرکوز رکھے گا۔

گروپ کی سطح پر، تمام عملیات میں باہمی تعاون کو بڑھانے، کاروباری کارکردگی کو بہتر بنانے اور دستیاب وسائل کے استعمال کو مزید موثر بنانے پر توجہ دی جائے گی۔ مینوفیکچرنگ کی صلاحیتوں، کوالٹی سسٹمز اور خصوصیات والی ادویات کے پورٹ فولیو میں مسلسل سرمایہ کاری گروپ کی طویل مدتی ترقی کے اہداف کی معاونت کرے گی، جبکہ 'سرل بائیو فارما' بائیولوجیکل ادویات کے کاروبار کو فروغ دینے اور اسٹریٹجک شراکت داریوں کو آگے بڑھانے کے لیے ایک مخصوص پلیٹ فارم فراہم کرتی ہے۔

بین الاقوامی منڈیاں گروپ کی تنوع (Diversification) کی حکمت عملی کے لیے ایک اہم ذریعہ بنی رہیں گی۔ اس سہ ماہی کے دوران برآمدی فروخت میں شاندار نمو کی بنیاد پر، گروپ موجودہ منڈیوں میں اپنی موجودگی کو مضبوط بنانے اور مصنوعات کی رجسٹریشن، بہتر ریگولیٹری صلاحیتوں اور قابلِ اعتماد سپلائی چین کے ذریعے نئے خطوں میں توسّع حاصل کرنے کی کوشش کرے گا۔

گروپ کاروباری توسّع کو لاگت کے منظم انتظام، دانشمندانہ سرمائے کی تخصیص اور ورکنگ کیپیٹل کے موثر انتظام کے ساتھ جوڑتے ہوئے ترقی کے لیے ایک متوازن نقطہ نظر اپنائے رکھے گا۔ ان ترجیحات کے ذریعے، گروپ اپنی لچک کو مضبوط بنانے، شیئر ہولڈرز کے منافع کو بڑھانے اور تمام اسٹیک ہولڈرز کے لیے پائیدار طویل مدتی قدر پیدا کرنے کا عزم رکھتا ہے۔

بورڈ کے لیے اور اس کی جانب سے

طاہر احمد
چیف ایگزیکٹو آفیسر

ارشد انیس
ڈائریکٹر

کراچی: 21 اکتوبر 2026

ڈائریکٹرز کنسولیڈیٹڈ رپورٹ برائے حصص یافتگان

ہمیں خوشی ہے کہ ہم گروپ کی 30 ستمبر 2026 کو ختم ہونے والی سہ ماہی کے متفقہ (Consolidated) عبوری مالیاتی گوشوارے پیش کر رہے ہیں۔ یہ مالیاتی گوشوارے بین الاقوامی اکاؤنٹنگ اسٹینڈرڈ "34 (IAS) – عبوری مالیاتی رپورٹنگ" کے تقاضوں کے مطابق تیار کیے گئے ہیں۔ ڈائریکٹرز کی یہ رپورٹ کمپنیز ایکٹ 2017 کی دفعہ 227 اور لسٹڈ کمپنیز (کارپوریٹ گورننس کے ضابطہ اخلاق) ریگولیشنز 2019 کے باب XII کے تحت تیار کی گئی ہے۔

مالی جھلکیاں

گروپ نے 11.18 ارب روپے کی آمدنی رپورٹ کی، جو گزشتہ سال کے مقابلے میں 15.24% کا اضافہ ظاہر کرتی ہے۔ فروخت میں نمایاں اضافہ بہتر عملی کارکردگی بالخصوص سپلائی چین کے عمل کو بہتر بنانے اور مالی وسائل کے مؤثر استعمال کے باعث ہوا ہے۔ مجموعی منافع کا مارجن 57.23% تک بہتر ہوا، جو سال بہ سال 3.15 فیصد کا اضافہ ظاہر کرتا ہے۔ یہ بہتری بنیادی طور پر قیمتوں میں ایڈجسٹمنٹ اور مصنوعات کے مجموعے میں سازگار تبدیلی کے نتیجے میں ہوئی۔

آپریٹنگ اخراجات میں معمولی اضافے کے جزوی اثرات کے باوجود، زیادہ فروخت اور مجموعی منافع کے بہتر مارجن کی بدولت آپریٹنگ منافع میں سال بہ سال 22% اضافہ ہوا۔

گروپ نے بعد از ٹیکس 1,195 ملین روپے کا منافع ریکارڈ کیا، جو گزشتہ سال کی اسی سہ ماہی میں 914 ملین روپے کے مقابلے میں 31% کی نمو ظاہر کرتا ہے۔

ذیل میں 30 ستمبر 2026 کو ختم ہونے والے تین ماہ کے مالیاتی نتائج کا خلاصہ پیش کیا جا رہا ہے:

اختتام پذیر سہ ماہی		
30 ستمبر 2026	30 ستمبر 2025	
(پاکستانی روپے ہزاروں میں)		
11,175,336	9,697,271	گاہکوں کے ساتھ معاہدوں سے آمدنی
(4,779,268)	(4,452,970)	فروخت کی لاگت
6,396,068	**5,244,301**	مجموعی منافع
(3,307,409)	(2,843,382)	ترسیل کے اخراجات
(698,529)	(492,208)	انتظامی اخراجات
(209,785)	(124,942)	دیگر اخراجات
49,758	39,396	دیگر آمدنی
2,230,103	**1,823,165**	آپریٹنگ منافع
(297,453)	(288,407)	مالیاتی اخراجات
1,932,650	**1,534,758**	لیویز اور انکم ٹیکس سے قبل منافع
(4,885)	(20,045)	لیویز – کم از کم ٹیکس اور حتمی ٹیکس
1,927,765	**1,514,713**	انکم ٹیکس سے قبل منافع
(732,290)	(600,561)	انکم ٹیکس (اخراجات) / کریڈٹ
1,195,475	**914,152**	اس عرصے کا منافع

CONSOLIDATED CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION

As at September 30, 2026

	Note	(Un-audited) September 30, 2026	(Audited) June 30, 2026
ASSETS		(Rupees in '000)	
Non-current assets			
Property, plant and equipment	5	**12,047,082**	12,120,277
Right-of-use asset		**27,381**	31,110
Investment properties		**6,183,249**	6,198,518
Intangibles		**2,995,862**	2,996,300
Deferred tax asset		**219,950**	220,889
Long-term deposits		**59,174**	21,439
		21,532,698	21,588,533
Current assets			
Inventories		**7,053,443**	7,532,554
Trade Receivables	6	**15,481,709**	12,348,039
Loans and advances		**1,788,632**	1,742,694
Trade deposits and short-term prepayments		**509,664**	465,593
Other receivables	7	**2,468,501**	2,858,288
Short-term investment at amortised cost		**253,834**	400,000
Taxation - payments less provision		**1,320,256**	1,805,713
Tax refunds due from government - Sales tax		**210,451**	245,452
Cash and bank balances		**1,499,765**	2,474,924
		30,586,255	29,873,257
Total assets		**52,118,953**	51,461,790
EQUITY AND LIABILITIES			
EQUITY			
Issued, subscribed and paid-up capital		**5,882,186**	5,882,186
Share premium		**9,085,133**	9,085,133
Unappropriated profit		**12,613,846**	11,387,399
General reserve		**280,251**	280,251
Revaluation surplus on property, plant and equipment		**6,713,302**	6,793,804
Attributable to owners of The Searle Company Limited - Holding Company		**34,574,718**	33,428,773
Non-controlling interests		**967,890**	913,860
		35,542,608	34,342,633
LIABILITIES			
Non-current liabilities			
Long-term borrowings	8	**116,457**	127,410
Employee benefit obligations		**52,904**	58,506
Lease liability		**40,337**	43,470
		209,698	229,386
Current liabilities			
Trade and other payables	9	**7,146,418**	8,588,301
Short-term borrowings	10	**8,826,336**	7,852,994
Contract liabilities		**140,706**	194,872
Unpaid dividend		**195,736**	195,928
Unclaimed dividend		**43,407**	43,632
Current portion of lease liability		**14,044**	14,044
		16,366,647	16,889,771
Total liabilities		**16,576,345**	17,119,157
Contingencies and commitments	11		
Total equity and liabilities		**52,118,953**	51,461,790

The annexed notes from 1 to 19 form an integral part of these consolidated condensed interim financial statements

Chief Executive | Director | Chief Financial Officer

CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the period ended September 30, 2026 - Unaudited

	Note	September 30, 2026	September 30, 2025
		(Rupees in '000)	
Revenue from contract with customers	12	**11,175,336**	9,697,271
Cost of sales		**(4,779,268)**	(4,452,970)
Gross profit		**6,396,068**	5,244,301
Distribution costs		**(3,307,409)**	(2,843,382)
Administrative expenses		**(698,529)**	(492,208)
Other operating expenses		**(209,785)**	(124,942)
Other income		**49,758**	39,396
Profit from operations		**2,230,103**	1,823,165
Finance cost		**(297,453)**	(288,407)
Profit before levies and income tax		**1,932,650**	1,534,758
Levies - minimum tax and final tax		**(4,885)**	(20,045)
Profit before income tax		**1,927,765**	1,514,713
Taxation		**(732,290)**	(600,561)
Profit for the period		**1,195,475**	914,152
Profit is attributable to:			
Owners of The Searle Company Limited - Holding Company		**1,145,945**	903,082
Non-controlling interests		**49,530**	11,070
		1,195,475	914,152
			(Re-stated)
Basic & diluted earnings per share	13	**1.95**	1.54

The annexed notes from 1 to 19 form an integral part of these consolidated condensed interim financial statements

Chief Executive



Director

Chief Financial Officer

CONSOLIDATED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY

For the period ended September 30, 2026 - Unaudited

	Capital reserves			Revenue reserves				
	Share capital	Share premium account	Revaluation surplus on Property, plant & equipment	General reserve	Unappro -priated profits	Sub-Total reserves	Non-Controlling interest	Total
	(Rupees in '000)							
Balance as at July 01, 2025 - (Audited)	5,114,945	9,085,133	6,178,180	280,251	11,430,588	26,974,152	803,687	32,892,784
Total comprehensive income for the period								
- Profit after tax	-	-	-	-	903,082	903,082	11,070	914,152
Contribution from non controlling interest as a non-redeemable convertible loan	-	-	-	-	-	-	3,000	3,000
Transfer of incremental depreciation - net of deferred tax	-	-	(60,797)	-	60,797	-	-	-
Balance as at September 30, 2025 - (Unaudited)	5,114,945	9,085,133	6,117,383	280,251	12,394,467	27,877,234	817,757	33,809,936
Balance as at July 01, 2026 - (Audited)	**5,882,186**	**9,085,133**	**6,793,804**	**280,251**	**11,387,399**	**27,546,587**	**913,860**	**34,342,633**
Total comprehensive income for the period								
- Profit after tax	**-**	**-**	**-**	**-**	**1,145,945**	**1,145,945**	**49,530**	**1,195,475**
Transfer of incremental depreciation - net of deferred tax	**-**	**-**	**(80,502)**	**-**	**80,502**	**-**	**-**	**-**
Contribution from non controlling interest as a non-redeemable convertible loan	**-**	**-**	**-**	**-**	**-**	**-**	**4,500**	**4,500**
Balance as at September 30, 2026 - (Unaudited)	**5,882,186**	**9,085,133**	**6,713,302**	**280,251**	**12,613,846**	**28,692,532**	**967,890**	**35,542,608**

The annexed notes from 1 to 19 form an integral part of these consolidated condensed interim financial statements

Chief Executive | Director | Chief Financial Officer

CONSOLIDATED CONDENSED INTERIM STATEMENT OF CASH FLOWS

For the period ended September 30, 2026 - Unaudited

	Note	September 30 2026	September 30 2025
		(Rupees in '000)	
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	14	**(2,185,188)**	667,731
Employee benefit obligations paid		**(6,952)**	(1,942)
Finance cost paid		**(269,276)**	(285,878)
Income tax paid		**(250,779)**	(155,495)
(Increase) / decrease in long-term deposits		**(37,735)**	1,920
Lease rentals paid		**(10,653)**	(7,409)
Decrease / (increase) in long-term loans and advances		**-**	15
Net cash generated from operating activities		**(2,760,583)**	218,942
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		**(268,820)**	(97,994)
Sale proceeds on disposal of property, plant and equipment		**47,555**	45
Additions to investment properties		**(9,783)**	(454)
Net cash inflow against disposal of subsidiary companies		**650,000**	-
Net cash used in investing activities		**418,952**	(98,403)
CASH FLOWS FROM FINANCING ACTIVITIES			
Dividend paid		**(417)**	(137)
Non - redeemable convertible loan		**4,500**	3,000
Proceeds/(Repayment) of borrowings		**(10,953)**	(3,276)
Proceeds/(Repayment) from/of short-term financing		**-**	(300,000)
Proceeds of short-term islamic finance (Sukuk)		**2,250,000**	-
Repayment of running musharaka		**(326,676)**	192,718
Net cash generated from / (used in) financing activities		**1,916,454**	(107,695)
Net increase in cash and cash equivalents		**(425,177)**	12,844
Cash and cash equivalents at beginning of the period		**1,578,001**	(896,455)
Cash and cash equivalents at end of the period	15	**1,152,824**	(883,611)

The annexed notes from 1 to 19 form an integral part of these consolidated condensed interim financial statements

Chief Executive | Director | Chief Financial Officer

1. LEGAL STATUS AND OPERATIONS

1.1 The Searle Company Limited (the Company) was incorporated in Pakistan as a private limited company in October 1965. In November 1993, the Company was converted into a public limited company under the repealed Companies Ordinance, 1984 (now the Companies Act, 2017). Its shares are quoted on the Pakistan Stock Exchange Limited (PSX). The Company is principally engaged in the manufacturing of pharmaceutical and other consumer products. The registered office of the Company is situated at One IBL Centre 2nd Floor, Plot No. 1, Block 7 & 8 Dehli Mercantile Muslim Cooperative Housing Society, Tipu Sultan Road off Shahrah-e-Faisal, Karachi.

International Brands (Private) Limited is the Parent Company, which holds 50.23% (June 30, 2026: 50.03%) shareholding in the Company.

Following are the subsidiary companies:

	Principal place of business	Effective %age of holding	
		September 30 2026	June 30 2026
Listed Company			
- IBL HealthCare Limited	Pakistan	**74.19%**	74.19%
Unlisted Companies			
- Searle Pharmaceuticals (Private) Limited		**100.00%**	100.00%
- Searle Laboratories (Private) Limited		**100.00%**	100.00%
- Searle Biosciences (Private) Limited		**100.00%**	100.00%
- IBL Future Technologies (Private) Limited		**100.00%**	100.00%
- Searle IV Solutions (Private) Limited		**100.00%**	100.00%
- Stellar Ventures (Private) Limited		**100.00%**	100.00%
- IBL Frontier Markets (Private) Limited *		**100.00%**	100.00%
- Prime Health (Private) Limited *		**100.00%**	100.00%
- Mycart (Private) Limited *		**50.00%**	50.00%
- Searle Biopharma (Private) Limited [formerly Nextar Pharma (Private) Limited] **		**87.20%**	87.20%

** Searle Biopharma (Private) Limited is the subsidiary of Searle Biosciences (Private) Limited being the indirect subsidiary of the Parent Company.*

** MyCart (Private) Limited, IBL Frontier Markets (Private) Limited and Prime Health MyCart (Private) Limited are the subsidiaries of Stellar Ventures (Private) Limited being the indirect subsidiary of the Parent Company.*

2 BASIS OF PREPARATION

2.1 Statement of compliance

2.1.1 These consolidated condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

- International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and

- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

2.1.2 These consolidated condensed interim financial statements do not include all the information required for a full set of financial statements and should be read in conjunction with the audited annual unconsolidated financial statements of the Company as at and for the year ended June 30, 2026.

2.1.3 Functional and presentation currency

These consolidated condensed interim financial statements are presented in Pakistan Rupees which is the Company's functional and presentation currency. All financial information presented in Pakistani Rupees have been rounded off to the nearest thousand Rupees except where stated otherwise.

3. MATERIAL ACCOUNTING POLICIES INFORMATION

3.1 The accounting policies and methods of computation adopted in the preparation of these consolidated condensed interim financial statements are the same as those applied in the preparation of the audited annual consolidated financial statements of the Company as at and for the year ended June 30, 2026.

3.2 Changes in accounting standards, interpretations and pronouncements

a) Standards and amendments to approved accounting standards that are effective

There are certain standards, amendments and interpretations to the accounting and reporting standards which are mandatory for the Group's annual accounting period which began on July 1, 2026. However, these do not have any significant impact on the Group's financial reporting.

b) Standards and amendments to approved accounting standards that are not yet effective

There are certain new standards and amendments that will be applicable to the Group for its annual periods beginning on or after July 1, 2027. However, these will not have any impact on the Group's financial reporting and, therefore, have not been disclosed in these unconsolidated condensed interim financial statements.

4. ACCOUNTING ESTIMATES, JUDGEMENTS AND FINANCIAL RISK MANAGEMENT

The preparation of the consolidated condensed interim financial statements in conformity with accounting and reporting standards, as applicable in Pakistan, requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The significant judgements made by the management in the preparation of this consolidated condensed interim financial information are the same as those that were applied to the annual audited consolidated financial statements as at and for the year ended June 30, 2026.

The Group's financial risk management objectives and policies are consistent with those disclosed in the annual audited consolidated financial statements as at and for the year ended June 30, 2026.

5. PROPERTY, PLANT AND EQUIPMENT

	(Unaudited) September 30 2026	(Audited) June 30, 2026
	(Rupees in '000)	
Operating assets	**11,366,181**	11,615,907
Capital work-in-progress - at cost	**680,901**	504,370
	12,047,082	12,120,277

6 TRADE RECEIVABLES

	(Unaudited) September 30 2026	(Audited) June 30, 2026
	(Rupees in '000)	
Considered good		
- Export receivables, secured	**974,974**	643,812
- Due from related parties, unsecured	**11,082,900**	9,256,799
- Others, unsecured	**3,665,741**	2,689,334
	15,723,615	12,589,945
Less: allowance for expected credit losses	**(241,906)**	(241,906)
	15,481,709	12,348,039

	(Unaudited) September 30 2026	(Audited) June 30, 2026
	(Rupees in '000)	
7 OTHER RECEIVABLES - considered good		
Receivables from related parties		
Due from Ultimate Parent Company and associated companies:		
- International Brands (Private) Limited	**572,303**	386,091
- IBL Operations (Private) Limited	**150,081**	149,262
- Universal Ventures (Private) Limited	**200,044**	200,044
- Mywater (Private) Limited	**-**	3,608
- IBL Logistics (Private) Limited	**252**	252
- United Brands Limited against:	**159**	50
	922,839	739,307
Due from other related party:		
- United Retail (SMC- Private) Limited	**157,311**	133,325
- Universal Retail (SMC- Private) Limited	**269,569**	247,539
	426,880	380,864
Surplus arising under retirement benefit fund	**5,250**	5,250
Receivables from other than related parties		
Noventa Pharma (Private) Limited against:		
Sale of subsidiary	**751,121**	1,401,121
Others, considered good	**362,411**	331,746
	2,468,501	2,858,288
8. LONG-TERM BORROWINGS		
Islamic		
Diminishing musharika	**116,457**	127,410

8.1 During the last year, the Parent Company obtained diminishing musharakah financing of Rs. 145 million from First Habib Modaraba for acquisition of four vehicles. The facilities carry profit at 3 month KIBOR plus 1% (with a minimum of 5%) and are repayable over a five years term through a monthly buy out of Musharakah units.

These arrangements are secured through hypothecation over the financed vehicles, comprehensive takaful assigned to the Modaraba, and retention of vehicle title in the name of First Habib Modaraba until full settlement.

		(Unaudited) September 30 2026	(Audited) June 30, 2026
9.	**TRADE AND OTHER PAYABLES**	(Rupees in '000)	
	Creditors	**1,991,555**	2,025,335
	Salaries and benefits payable	**-**	13,938
	Bills payable in foreign currency	**662,117**	1,720,080
	Royalty payable	**29,476**	39,868
	Accrued liabilities	**2,710,076**	2,987,539
	Payable to provident fund	**42,714**	50,049
	Taxes deducted at source and payable to statutory authorities	**717,205**	877,788
	Accrued markup	**257,074**	236,417
	Workers' Profit Participation Fund	**364,401**	269,505
	Workers' Welfare Fund	**138,853**	117,943
	Other liabilities	**232,947**	249,839
		7,146,418	8,588,301
10.	**SHORT-TERM BORROWINGS**		
	Secured borrowings		
	Conventional:		
	Running finance under mark-up arrangements - note 10.1	**346,941**	1,296,923
	Export refinance facility	**-**	100,000
	Short-term finance facility	**500,000**	500,000
		846,941	1,896,923
	Islamic:		
	Running musharaka - note 10.1 to 10.1.1	**4,530,554**	5,807,862
	Export refinance facility	**1,150,000**	100,000
	Current portion of long term borrowings	**37,430**	36,798
		5,717,984	5,944,660
	Unsecured borrowings		
	International Brands (Private) Limited	**11,411**	11,411
	Short-term Islamic finance (Sukuk) - note 10.3	**2,250,000**	-
		8,826,336	7,852,994

10.1 The Parent Company has entered into running finance under mark-up arrangements from various banks amounting to Rs. 10,200 million (June 30, 2026: Rs. 9,700 million) which include financing facilities obtained under Islamic mode amounting to Rs. 8,650 million (June 30, 2026: Rs. 7,650 million). The arrangements are secured jointly by a registered mortgage of Rs. 2,642 million (June 30, 2026: Rs. 2,813.5 million) of immovable property together with a joint pari passu charge on all current assets of the Company to the extent of Rs. 14,890 million (June 30, 2026: Rs. 14,583.67 million).

10.1.1 The rates of mark-up ranged between 12.90 % to 13.79 % (June 30, 2026: 11.74% to 13.99%) per annum.
The rates of profit ranged between 12.19 % to 13.29 % (June 30, 2026: 10.58% to 13.03%) per annum.

10.2 During the period, the Parent Company has obtained short-term financing in the form of Sukuk amounting to Rs. 2,250 million under a Shariah-compliant Islamic financing arrangement for meeting its working capital and general business requirements. The financing is unsecured, privately placed and taken as a redeemable capital under Section 66 of the Companies Act 2017. The tenor of this financing is 6 months and is priced at 3 months Kibor + 0.75% which is payable at maturity along with the principal.

10.3 IBL HealthCare Limited, obtained running musharakah facilities from commercial banks amounting to Rs. 439 million (June 30, 2026: Rs. 439 million) out of which the amount availed at the period ended was Rs. Nil (June 30, 2026: Rs. 6.72 million). Rates of profit range from one month KIBOR plus 1% (June 30, 2026: one month KIBOR plus 1%) to three months KIBOR plus 1.25% (June 30, 2026: three month KIBOR plus 1.25%) per annum. These facilities have been secured by way of hypothecation of first pari passu charge over present and future current assets amounting to Rs. 585 million (June 30, 2026: Rs. 585 million).

11. CONTINGENCIES AND COMMITMENTS

11.1 Contingencies

There has been no significant change in the status of contingencies in the current period as reported in the note 28 of the annual audited consolidated financial statements of the Group for the year ended June 30, 2026.

11.2 Commitments

11.2.1 The facility for opening letters of credit and guarantees of the Parent Company as at September 30, 2026 amounted to Rs. 4,295 million (June 30, 2026: Rs. 4,015 million) of which the amount remaining unutilised as at period ended September 30, 2026 amounted to Rs. 2,955 million (June 30, 2026: Rs. 2,716 million).

12. REVENUE FROM CONTRACT WITH CUSTOMERS

	(Unaudited)	
	September 30 2026	September 30 2025
	(Rupees in '000)	
Gross sales		
Local sales	**11,578,605**	10,017,236
Export sales	**1,140,041**	851,775
	12,718,646	10,869,011
Toll manufacturing	**7,931**	1,245
	12,726,577	10,870,256
Sales tax	**(265,993)**	(243,416)
	12,460,584	10,626,840
Less:		
Discounts, rebates and allowances	**(876,544)**	(564,697)
Sales returns	**(408,704)**	(364,872)
	(1,285,248)	(929,569)
	11,175,336	9,697,271

		(Unaudited)	
		September 30	September 30
13.	**BASIC AND DILUTED EARNINGS PER SHARE**	**2026**	2025
	Profit for the period (in thousand)	**1,145,945**	903,082
	Weighted average number of outstanding shares at the end of the period (in thousand)	**588,219**	588,219
			(Re-stated)
	Basic and diluted earnings per share (Rupees)	**1.95**	1.54

		(Unaudited)	
		September 30	September 30
		2026	2025
		(Rupees in '000)	
14.	**CASH GENERATED FROM OPERATIONS**		
	Profit before income tax	**1,932,650**	1,534,758
	Add / (less): Adjustments for non-cash charges and other items		
	Depreciation on property, plant and equipment	**243,589**	193,984
	Depreciation on investment property	**25,052**	25,162
	Depreciation on right-of-use-asset	**3,729**	2,555
	Gain on disposal of property, plant and equipment	**50,871**	217
	Amortisation	**438**	4,098
	Provision for retirement benefits obligation	**1,350**	1,350
	Finance cost	**289,933**	283,723
	Interest on lease liability	**7,520**	4,684
	Profit before working capital changes	**2,555,132**	2,050,531
	Effect on cash flow due to working capital changes		
	(Increase) / decrease in current assets		
	Inventories	**479,111**	96,224
	Trade receivables	**(3,133,670)**	(1,521,781)
	Loans and advances	**(45,938)**	(371,623)
	Trade deposits and short-term prepayments	**(44,071)**	(85,018)
	Short-term investment at amortised cost	**(253,834)**	100,000
	Tax refunds due from government - Sales tax	**35,001**	104,651
	Other receivables	**(260,213)**	(14,364)
		(3,223,614)	(1,691,911)
	Increase / (decrease) in current liabilities		
	Trade and other payables	**(1,462,540)**	317,971
	Contract liabilities	**(54,166)**	(8,860)
	Cash generated from operations	**(2,185,188)**	667,731
15.	**CASH AND CASH EQUIVALENTS**		
	Cash and bank balances	**1,499,765**	277,948
	Short term running finances - note 10	**(346,941)**	(1,161,559)
		1,152,824	(883,611)

16. SEGMENT INFORMATION

Based on internal management reporting structure for the period, no reportable segments were identified that were of continuing significance for decision making.

17. DISCLOSURE OF TRANSACTIONS BETWEEN THE GROUP AND RELATED PARTIES

The related parties include associated companies, staff retirement funds, directors, key management personnel and close family members of directors and key management personnel. The Group in the normal course of business carries out transactions with various related parties. The Group enters into transactions with related parties on the basis of mutually agreed terms. Significant transactions with related parties are as follows:

		(Unaudited)	
		September 30	September 30
Nature of relationship	**Nature of transactions**	**2026**	2025
		(Rupees in '000)	
Ultimate parent company	- Corporate service charges	**81,150**	24,200
	- Rent income	**5,906**	5,459
	- Income from provision of amenities	**4,103**	3,810
Staff retirement benefits	- Contributions to provident fund	**69,212**	67,923
	- Benefits paid	**-**	14,283
Associated companies	- Revenue	**6,562,784**	6,502,514
	- Salaries and wages	**2,678**	3,554
	- Carriage and duties	**-**	11,091
	- Discounts claimed	**31,200**	935
	- Rent expense	**21,865**	21,230
	- Rent income	**15,589**	13,880
	- Stock claims	**37,774**	10
	- Internet services	**27,282**	11,933
	- Income from provision of amenities	**50,650**	38,100
	- Donations	**5,850**	5,000
	- Incentives to field force staff	**5,704**	-
	- Repair & maintenance	**284**	153
	- Purchases of Furniture	**8,018**	-
	- Others	**2,301**	-
Key management employees compensation	- Salaries and other employee benefits	**87,489**	70,510
	- Contributions to a provident fund	**9,672**	9,210

The status of outstanding balances with related parties as at reporting date is included in the respective notes to the unconsolidated condensed interim financial statements.

Notes to the Consolidated Condensed Interim Financial Statements
For the period ended September 30, 2026 - Unaudited

18. GENERAL

18.1. Non-adjusting events after reporting date

The Board of Directors, of the Parent Company, in their meeting held on September 25, 2026, proposed a final cash dividend of Re. 1 per share (Rs. 588.22 million) for the year ended June 30, 2026. The proposal is subject to approval by the members at the Annual General Meeting scheduled to be held on October 22, 2026. In accordance with IAS 10 'Events after the Reporting Period', this proposed dividend has not been recognised as a liability in these condensed interim financial statements.

19. DATE OF AUTHORISATION FOR ISSUE

This consolidated condensed interim financial information was approved and authorised for issue by the Board of Directors of the Parent Company on October 21, 2026.

Chief Executive	Director	Chief Financial Officer

SEARLE
THE SEARLE COMPANY LIMITED
2nd Floor, One IBL Centre, Plot# 1, Block 7 & 8,
Dehli Mercantile Muslim Cooperative Housing Society
(DMCHS) Tipu Sultan Road, Off. Shahrah-e-Faisal, Karachi
URL: www.searlecompany.com